GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

GSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO.

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and ...

Find the latest GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) stock quote, history, news and other vital information to help you with your stock trading and investing.